Nurix Therapeutics マネジメント
マネジメント 基準チェック /44
Nurix Therapeuticsの CEO はArthur Sandsで、 Sep2014年に任命され、 の在任期間は 10.17年です。 の年間総報酬は$ 4.36Mで、 13.5%給与と86.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.44%を直接所有しており、その価値は$ 6.80M 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と4.2年です。
主要情報
Arthur Sands
最高経営責任者
US$4.4m
報酬総額
| CEO給与比率 | 13.5% |
| CEO在任期間 | 10.2yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 4.4yrs |
| 取締役会の平均在任期間 | 4.2yrs |
経営陣の近況
Recent updates
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%
Nov 07
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth
Oct 31Nurix: An Attractive Early-Stage Biotech Play
Oct 08Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares
Sep 07Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data
Sep 04Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans
Jul 15Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Jun 19What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You
May 29Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Aug 31 2024 | n/a | n/a | -US$177m |
| May 31 2024 | n/a | n/a | -US$165m |
| Feb 29 2024 | n/a | n/a | -US$145m |
| Nov 30 2023 | US$4m | US$591k | -US$144m |
| Aug 31 2023 | n/a | n/a | -US$149m |
| May 31 2023 | n/a | n/a | -US$157m |
| Feb 28 2023 | n/a | n/a | -US$179m |
| Nov 30 2022 | US$9m | US$572k | -US$180m |
| Aug 31 2022 | n/a | n/a | -US$171m |
| May 31 2022 | n/a | n/a | -US$154m |
| Feb 28 2022 | n/a | n/a | -US$135m |
| Nov 30 2021 | US$5m | US$539k | -US$117m |
| Aug 31 2021 | n/a | n/a | -US$99m |
| May 31 2021 | n/a | n/a | -US$89m |
| Feb 28 2021 | n/a | n/a | -US$63m |
| Nov 30 2020 | US$17m | US$521k | -US$43m |
| Aug 31 2020 | n/a | n/a | -US$37m |
| May 31 2020 | n/a | n/a | -US$21m |
| Feb 29 2020 | n/a | n/a | -US$24m |
| Nov 30 2019 | US$1m | US$474k | -US$22m |
報酬と市場: Arthurの 総報酬 ($USD 4.36M ) は、 US市場 ($USD 5.50M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Arthurの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Arthur Sands (62 yo)
10.2yrs
在職期間
US$4,363,120
報酬
Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 10.2yrs | US$4.36m | 0.44% $ 6.8m | |
| Chief Financial Officer | 8.7yrs | US$1.61m | 0.048% $ 743.6k | |
| Chief Scientific Officer | 4.4yrs | US$1.63m | 0.072% $ 1.1m | |
| Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Senior Accounting Manager | no data | データなし | データなし | |
| Chief Technical Officer | less than a year | データなし | データなし | |
| Chief Legal Officer | 5.2yrs | US$1.65m | 0.040% $ 619.3k | |
| Chief People Officer | 2.3yrs | データなし | データなし | |
| Chief Business Officer | 4.3yrs | データなし | データなし | |
| Senior VP & Head of Early Drug Discovery | 3.8yrs | データなし | データなし |
4.4yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: NRIXの経営陣は 経験豊富 であると考えられます ( 4.4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 10.2yrs | US$4.36m | 0.44% $ 6.8m | |
| Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Chairman | 5.3yrs | US$238.29k | 0% $ 0 | |
| Member of Medical Advisory Board | 1.8yrs | データなし | データなし | |
| Independent Director | 3.1yrs | US$225.79k | 0% $ 0 | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.3yrs | US$228.29k | 0% $ 0 | |
| Independent Director | 8.6yrs | US$263.29k | 0.047% $ 735.0k | |
| Independent Director | 3.1yrs | US$225.79k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$223.29k | 0% $ 0 |
4.2yrs
平均在職期間
67.5yo
平均年齢
経験豊富なボード: NRIXの 取締役会 は 経験豊富 であると考えられます ( 4.2年の平均在任期間)。